|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.140 USD | -0.93% |
|
+5.94% | +39.87% |
| 06-15 | Compugen Ltd. - Special Call | |
| 06-11 | Compugen Presents Trial-In-Progress Poster On MAIA-Ovarian Phase 1 Study Of COM701 At ESMO Gynaecological Cancers Congress 2026 | CI |
Company Valuation: Compugen Ltd.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 370.7 | 62 | 174.9 | 137 | 143.1 | 202.4 | - | - |
| Change | - | -83.28% | 182.09% | -21.67% | 4.47% | 41.44% | - | - |
| Enterprise Value (EV) | 370.7 | 62 | 174.9 | 137 | 143.1 | 202.4 | 202.4 | 202.4 |
| Change | - | -83.28% | 182.09% | -21.67% | 4.47% | 41.44% | 0% | 0% |
| P/E | -10.5x | -1.84x | -9.43x | -9.56x | 4.03x | -7.38x | -7.48x | -7.81x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0.38x | 0.2x | 0.4x | -0x | 0x | 5.42x | 1.86x |
| Capitalization / Revenue | 61.8x | 8.27x | 5.23x | 4.92x | 1.97x | 21.5x | 12.6x | 8.19x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 21.5x | 12.6x | 8.19x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | -0x | -0x | 0x | -6.88x | -7.27x | -6.86x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.41 | -0.39 | -0.21 | -0.16 | 0.38 | -0.29 | -0.286 | -0.274 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 6 | 7.5 | 33.46 | 27.86 | 72.76 | 9.414 | 16.05 | 24.7 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -35.07 | -35.37 | -12.99 | -14.89 | 31.33 | -29.4 | -27.85 | -29.49 |
| Net income 1 | -34.2 | -33.69 | -18.75 | -14.23 | 35.34 | -27.6 | -28.01 | -27.71 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 4.300 | 0.716 | 1.980 | 1.530 | 1.530 | 2.140 | 2.140 | 2.140 |
| Nbr of stocks (in thousands) | 86,214 | 86,625 | 88,327 | 89,536 | 93,535 | 94,585 | - | - |
| Announcement Date | 2/24/22 | 2/27/23 | 3/5/24 | 3/4/25 | 3/2/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -7.45x | - | - | - | 204M | |
| 32.51x | 5.73x | 17.74x | 1.01% | 46.62B | |
| -24.23x | 362.81x | -23.24x | -.--% | 40.95B | |
| 23.52x | 2.66x | 11.48x | -.--% | 32.26B | |
| 43.26x | 4.35x | 27.86x | -.--% | 32.24B | |
| 30.17x | 7.79x | 20.04x | 0.42% | 25.53B | |
| 31.37x | 5.08x | 23.16x | -.--% | 15.27B | |
| 23.68x | 2.02x | 8.88x | 1.13% | 13.61B | |
| -22.39x | 14.68x | -21.96x | -.--% | 13.34B | |
| Average | 14.49x | 50.64x | 7.99x | 0.32% | 24.45B | |
| Weighted average by Cap. | 17.95x | 72.11x | 8.36x | 0.33% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- CGEN Stock
- Valuation Compugen Ltd.
Select your edition
All financial news and data tailored to specific country editions
